Argatroban clinical trials
Also written Novastan.
How each study uses argatroban is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the argatroban studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 30 Jun 2000 · ARGATROBAN · NDA 020883 (FDA, Drugs@FDA)
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
23 studies that test it; most in 2010 (3)
| Year | Studies |
|---|---|
| 2002 | 1 |
| 2003 | 2 |
| 2005 | 2 |
| 2009 | 2 |
| 2010 | 3 |
| 2011 | 1 |
| 2012 | 1 |
| 2015 | 1 |
| 2016 | 1 |
| 2017 | 1 |
| 2018 | 2 |
| 2019 | 1 |
| 2020 | 2 |
| 2021 | 2 |
| 2024 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 5 · Other 18
Tanabe Pharma Corporation (2) · Medical University of Vienna (2) · The University of Texas Health Science Center, Houston (2) · Tanabe Pharma GmbH (1) · Washington University School of Medicine (1) · Beijing Chao Yang Hospital (1) · Second Affiliated Hospital, School of Medicine, Zhejiang University (1) · General Hospital of Shenyang Military Region (1)
Often tested with
Tested in the same studies.
Eptifibatide (1) · Heparin, Low-Molecular-Weight (1) · Enoxaparin (1) · Tissue Plasminogen Activator (1) · Warfarin (1) · Lepirudin (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test argatroban.
- Jan 2027Comparing Anticoagulation Strategies Using UFH, Argatroban and LMWH for ECMO SupportPhase 4 · Medical University of Vienna
Studies
Open first, then newest update. How each study uses argatroban is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 23
- Comparing Anticoagulation Strategies Using UFH, Argatroban and LMWH for ECMO SupportRecruitingPhase 4Medical University of ViennaNCT06442267Written as Argatroban, 1 Mg/mL Intravenous SolutionHow we know
- Clinical Management of Argatroban in Patients With Heparin Induced Thrombocytopenia Type IICompletedPhase 2Tanabe Pharma CorporationNCT00861692Written as argatrobanHow we know
- Study on Safety and Effectiveness of Three Doses of Argatroban as Anticoagulant in Percutaneous Coronary Intervention (PCI)CompletedPhase 2Tanabe Pharma CorporationNCT00508924Written as ArgatrobanHow we know
- Safety of Argatroban Infusion in Conduction DisturbancesCompletedPhase 4Tanabe Pharma GmbHNCT05740371Written as ArgatrobanHow we know
- Multi-arm Optimization of Stroke ThrombolysisCompletedPhase 3Washington University School of MedicineNCT03735979Written as ArgatrobanHow we know
- Safety and Feasibility of Argatroban As Anticoagulant in Adults with ECMOCompletedPhase 2/3Medical University of ViennaNCT05226442Written as ArgatrobanHow we know
- Safety and Efficacy of Argatroban Applicated in Anticoagulation of V-V ECMOCompletedNot applicableBeijing Chao Yang HospitalNCT04925167Written as ArgatrobanHow we know
- Anticoagulation in Critically Ill Patients With COVID-19 (The IMPACT Trial)TerminatedPhase 4Weill Medical College of Cornell UniversityNCT04406389Written as ArgatrobanHow we know
- Efficacy Argatroban in Ischemic Stroke With Early Deterioration (EASE)CompletedPhase 4Second Affiliated Hospital, School of Medicine, Zhejiang UniversityNCT04275180Written as ArgatrobanHow we know
- Argatroban Plus R-tPA for Acute Ischemic StrokeCompletedPhase 4General Hospital of Shenyang Military RegionNCT03740958Written as ArgatrobanHow we know
- Thromboprophylaxis After Surgery for Gynecologic Malignancy in ChinaCompletedPhase 3Huazhong University of Science and TechnologyNCT02935530Written as ArgatrobanHow we know
- Argatroban Plus r-tPA for Posterior Circulation Infarction(AR-PCI)TerminatedPhase 4Hui-Sheng ChenNCT03506009Written as Argatroban combined with rt-PAHow we know
- Argatroban in Critically Ill Patients With Heparin ResistanceCompletedPhase 2Medical University InnsbruckNCT01734252Written as ArgatrobanHow we know
- Significance of Antibodies to Heparin/Platelet Factor 4 Complex in Vein Graft Patency and Potential Role of Argatroban for Prevention of Vein Graft OcclusionTerminatedPhase 4Massachusetts General HospitalNCT01246011Written as Argatroban and warfarinHow we know
- Safety and Feasibility of Argatroban, Tissue Plasminogen Activator and Intra-arterial Therapy in StrokeCompletedPhase 2The University of Texas Health Science Center, HoustonNCT02448069Written as ArgatrobanHow we know
- Randomized Controlled Trial of Argatroban With Tissue Plasminogen Activator (tPA) for Acute StrokeTerminatedPhase 2Andrew D. Barreto, MDNCT01464788Written as Low Dose ArgatrobanHow we know
- Argatroban for Preventing Occlusion and Restenosis After Intracranial and Extracranial Artery StentingCompletedPhase 4Jinling Hospital, ChinaNCT01163604Written as ArgatrobanHow we know
- Argatroban for Preventing Occlusion and Restenosis After Extracranial Vertebral Artery StentingCompletedPhase 4Xinfeng LiuNCT01980316Written as ArgatrobanHow we know
- Argatroban Stroke Treatment - A Pilot Safety StudyCompletedPhase 1/2The University of Texas Health Science Center, HoustonNCT00268762Written as argatrobanHow we know
- Argatroban Versus Lepirudin in Critically Ill PatientsTerminatedPhase 4Heinrich-Heine University, DuesseldorfNCT00798525Written as ArgatrobanHow we know
See all 23 studies that test argatroban →
As the comparator · 2 — what is tested is compared with argatroban
- A Phase I Study of the Co-administration of VLX-1005 and Argatroban in Healthy Human SubjectsCompletedPhase 1Veralox TherapeuticsNCT05325346Written as ArgatrobanHow we know
- Open-Label, Randomised, Active Controlled, Multi-Centre Phase 3 Study Safety and Efficacy of Danaparoid vs ArgatrobanTerminatedPhase 3Aspen Global IncorporatedNCT03809481Written as ArgatrobanHow we know
Codes
What other systems call argatroban · ClinicalTrials.gg INT002967
- MeSH (NLM) C031942argatrobanConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) IY90U61Z3SARGATROBANConfirmed FDA, NLM, Wikidata
- RxNorm 15202One source FDA
- Wikidata Q59400516argatroban monohydrateConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C28833ArgatrobanOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C031942 | argatroban | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | IY90U61Z3S | ARGATROBAN | Confirmed FDA, NLM, Wikidata |
| RxNorm | 15202 | — | One source FDA |
| Wikidata | Q59400516 | argatroban monohydrate | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C28833 | Argatroban | One source FDA |
Also registered as argatroban anhydrous (UNII OCY3U280Y3 · RxNorm 1546207), argatroban anhydrous, (21r)- (UNII 0DW7MIH1VX · RxNorm 15202), argatroban anhydrous, (21s)- (UNII 4YBM839JAC) and argatroban, (21r)- (UNII 88X69347Z5).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.